Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.21% | -65.84% | -91.70% | -60.67% | -26.56% |
| Total Depreciation and Amortization | 17.88% | 38.26% | 41.04% | 17.16% | 0.78% |
| Total Amortization of Deferred Charges | 30.13% | 16.78% | 17.75% | 27.05% | -11.16% |
| Total Other Non-Cash Items | -5.39% | 6.20% | 74.85% | 63.26% | 64.19% |
| Change in Net Operating Assets | -297.39% | -12.12% | 61.36% | -0.33% | -511.61% |
| Cash from Operations | -69.34% | -93.90% | -83.28% | -56.21% | -18.02% |
| Capital Expenditure | 92.26% | 91.74% | 61.49% | -95.82% | -22.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 92.26% | 91.74% | 61.49% | -95.82% | -22.90% |
| Total Debt Issued | -77.69% | -71.98% | -- | -- | 132.48% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.82% | -20.70% | -21.54% | -99.98% | 265.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -52.43% | -50.28% | 136.99% | 36.91% | 170.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.36% | -136.84% | 530.50% | -28.34% | 2,390.01% |